<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01594970</url>
  </required_header>
  <id_info>
    <org_study_id>APMA-001211</org_study_id>
    <nct_id>NCT01594970</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of bimatoprost 0.01% in subjects with
      elevated intraocular pressure (IOP) due to primary open-angle glaucoma (POAG) or ocular
      hypertension (OH).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of Ocular Hyperemia in the Study Eye on a 5-Point Scale</measure>
    <time_frame>Week 12</time_frame>
    <description>Hyperemia is the engorgement of the blood vessels (redness) of the eye. Hyperemia is graded in the study eye on a 5 point scale where 0=None (Normal), 0.5=Trace (Trace reddish pink with no more than slight perilimbal injection), 1=Mild (Mild flush reddish color), 2=Moderate (Bright red color), and 3=Severe (Deep, bright, diffuse redness). The numbers of participants in each severity grade are presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Intraocular Pressure (IOP)</measure>
    <time_frame>Baseline, Week 6, Week 12</time_frame>
    <description>IOP is a measure of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Percent Change From Baseline in IOP</measure>
    <time_frame>Baseline, Week 6, Week 12</time_frame>
    <description>IOP is a measure of the fluid pressure inside the eye. A negative number change response indicates a reduction in IOP (improvement).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline in Hyperemia Severity in the Study Eye</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Hyperemia is the engorgement of the blood vessels (redness) of the eye. Hyperemia was graded in the study eye on a 5 point scale where 0=None (Normal), 0.5=Trace (Trace reddish pink with no more than slight perilimbal injection), 1=Mild (Mild flush reddish color), 2=Moderate (Bright red color), and 3=Severe (Deep, bright, diffuse redness). 'Lower' categories refer to grades 0, 0.5 and 1, and 'higher' categories refer to grades 2 and 3. Change in hyperemia severity was classified as improved, no change or worsened based on the change in the hyperemia grading category from higher to lower, no change in category or lower to higher, respectively. The numbers of participants in each category are presented.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">800</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Bimatoprost 0.01% (Naive Monotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop in the affected eye(s), administered in the evening in previously treatment naive subjects for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bimatoprost 0.01% (Switched Monotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop in the affected eye(s), administered in the evening in subjects who were previously on another monotherapy treatment for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bimatoprost 0.01% (with Adjunctive Therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop in the affected eye(s), administered in the evening in subjects who are also receiving adjunctive therapy for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bimatoprost 0.01%</intervention_name>
    <description>1 drop in the affected eye(s), administered in the evening for 12 weeks.</description>
    <arm_group_label>Bimatoprost 0.01% (Naive Monotherapy)</arm_group_label>
    <arm_group_label>Bimatoprost 0.01% (Switched Monotherapy)</arm_group_label>
    <arm_group_label>Bimatoprost 0.01% (with Adjunctive Therapy)</arm_group_label>
    <other_name>LUMIGANÂ® 0.01%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elevated IOP due to either primary open-angle glaucoma or ocular hypertension

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2012</study_first_submitted>
  <study_first_submitted_qc>May 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2012</study_first_posted>
  <results_first_submitted>January 27, 2014</results_first_submitted>
  <results_first_submitted_qc>January 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 12, 2014</results_first_posted>
  <last_update_submitted>January 27, 2014</last_update_submitted>
  <last_update_submitted_qc>January 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bimatoprost</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bimatoprost 0.01% (Naive Monotherapy)</title>
          <description>1 drop in the affected eye(s), administered in the evening in previously treatment naive subjects for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Bimatoprost 0.01% (Switched Monotherapy)</title>
          <description>1 drop in the affected eye(s), administered in the evening in subjects who were previously on another monotherapy treatment for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Bimatoprost 0.01% (With Adjunctive Therapy)</title>
          <description>1 drop in the affected eye(s), administered in the evening in subjects who are also receiving adjunctive therapy for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="295"/>
                <participants group_id="P2" count="248"/>
                <participants group_id="P3" count="257"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
                <participants group_id="P2" count="166"/>
                <participants group_id="P3" count="191"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="82"/>
                <participants group_id="P3" count="66"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Non-Adverse Event Related</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bimatoprost 0.01% (Naive Monotherapy)</title>
          <description>1 drop in the affected eye(s), administered in the evening in previously treatment naive subjects for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Bimatoprost 0.01% (Switched Monotherapy)</title>
          <description>1 drop in the affected eye(s), administered in the evening in subjects who were previously on another monotherapy treatment for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Bimatoprost 0.01% (With Adjunctive Therapy)</title>
          <description>1 drop in the affected eye(s), administered in the evening in subjects who are also receiving adjunctive therapy for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="295"/>
            <count group_id="B2" value="248"/>
            <count group_id="B3" value="257"/>
            <count group_id="B4" value="800"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.0" spread="13.81"/>
                    <measurement group_id="B2" value="59.5" spread="13.23"/>
                    <measurement group_id="B3" value="61.2" spread="12.59"/>
                    <measurement group_id="B4" value="59.5" spread="13.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="152"/>
                    <measurement group_id="B4" value="420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Severity of Ocular Hyperemia in the Study Eye on a 5-Point Scale</title>
        <description>Hyperemia is the engorgement of the blood vessels (redness) of the eye. Hyperemia is graded in the study eye on a 5 point scale where 0=None (Normal), 0.5=Trace (Trace reddish pink with no more than slight perilimbal injection), 1=Mild (Mild flush reddish color), 2=Moderate (Bright red color), and 3=Severe (Deep, bright, diffuse redness). The numbers of participants in each severity grade are presented.</description>
        <time_frame>Week 12</time_frame>
        <population>Intent to Treat: all treated subjects with data at this time point</population>
        <group_list>
          <group group_id="O1">
            <title>Bimatoprost 0.01% (Naive Monotherapy)</title>
            <description>1 drop in the affected eye(s), administered in the evening in previously treatment naive subjects for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bimatoprost 0.01% (Switched Monotherapy)</title>
            <description>1 drop in the affected eye(s), administered in the evening in subjects who were previously on another monotherapy treatment for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Bimatoprost 0.01% (With Adjunctive Therapy)</title>
            <description>1 drop in the affected eye(s), administered in the evening in subjects who are also receiving adjunctive therapy for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Ocular Hyperemia in the Study Eye on a 5-Point Scale</title>
          <description>Hyperemia is the engorgement of the blood vessels (redness) of the eye. Hyperemia is graded in the study eye on a 5 point scale where 0=None (Normal), 0.5=Trace (Trace reddish pink with no more than slight perilimbal injection), 1=Mild (Mild flush reddish color), 2=Moderate (Bright red color), and 3=Severe (Deep, bright, diffuse redness). The numbers of participants in each severity grade are presented.</description>
          <population>Intent to Treat: all treated subjects with data at this time point</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trace</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Intraocular Pressure (IOP)</title>
        <description>IOP is a measure of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement).</description>
        <time_frame>Baseline, Week 6, Week 12</time_frame>
        <population>Intent to Treat: all treated subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Bimatoprost 0.01% (Naive Monotherapy)</title>
            <description>1 drop in the affected eye(s), administered in the evening in previously treatment naive subjects for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bimatoprost 0.01% (Switched Monotherapy)</title>
            <description>1 drop in the affected eye(s), administered in the evening in subjects who were previously on another monotherapy treatment for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Bimatoprost 0.01% (With Adjunctive Therapy)</title>
            <description>1 drop in the affected eye(s), administered in the evening in subjects who are also receiving adjunctive therapy for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Intraocular Pressure (IOP)</title>
          <description>IOP is a measure of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement).</description>
          <population>Intent to Treat: all treated subjects</population>
          <units>Millimeters of Mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" spread="5.39"/>
                    <measurement group_id="O2" value="17.0" spread="5.73"/>
                    <measurement group_id="O3" value="19.3" spread="6.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 6 (N=251, 204, 233)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="4.50"/>
                    <measurement group_id="O2" value="-2.6" spread="4.43"/>
                    <measurement group_id="O3" value="-3.2" spread="5.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12 (N=220, 165, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="4.42"/>
                    <measurement group_id="O2" value="-2.8" spread="4.68"/>
                    <measurement group_id="O3" value="-3.4" spread="6.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Percent Change From Baseline in IOP</title>
        <description>IOP is a measure of the fluid pressure inside the eye. A negative number change response indicates a reduction in IOP (improvement).</description>
        <time_frame>Baseline, Week 6, Week 12</time_frame>
        <population>Intent to Treat: all treated subjects with data at this time point</population>
        <group_list>
          <group group_id="O1">
            <title>Bimatoprost 0.01% (Naive Monotherapy)</title>
            <description>1 drop in the affected eye(s), administered in the evening in previously treatment naive subjects for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bimatoprost 0.01% (Switched Monotherapy)</title>
            <description>1 drop in the affected eye(s), administered in the evening in subjects who were previously on another monotherapy treatment for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Bimatoprost 0.01% (With Adjunctive Therapy)</title>
            <description>1 drop in the affected eye(s), administered in the evening in subjects who are also receiving adjunctive therapy for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Percent Change From Baseline in IOP</title>
          <description>IOP is a measure of the fluid pressure inside the eye. A negative number change response indicates a reduction in IOP (improvement).</description>
          <population>Intent to Treat: all treated subjects with data at this time point</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline at Week 6 (N=251, 204, 233)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.09" spread="17.023"/>
                    <measurement group_id="O2" value="-12.90" spread="18.912"/>
                    <measurement group_id="O3" value="-14.37" spread="20.883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Week 12 (N=220, 165, 191)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.22" spread="17.566"/>
                    <measurement group_id="O2" value="-12.81" spread="19.438"/>
                    <measurement group_id="O3" value="-14.25" spread="23.376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Hyperemia Severity in the Study Eye</title>
        <description>Hyperemia is the engorgement of the blood vessels (redness) of the eye. Hyperemia was graded in the study eye on a 5 point scale where 0=None (Normal), 0.5=Trace (Trace reddish pink with no more than slight perilimbal injection), 1=Mild (Mild flush reddish color), 2=Moderate (Bright red color), and 3=Severe (Deep, bright, diffuse redness). 'Lower' categories refer to grades 0, 0.5 and 1, and 'higher' categories refer to grades 2 and 3. Change in hyperemia severity was classified as improved, no change or worsened based on the change in the hyperemia grading category from higher to lower, no change in category or lower to higher, respectively. The numbers of participants in each category are presented.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent to Treat: all treated subjects with data at this time point</population>
        <group_list>
          <group group_id="O1">
            <title>Bimatoprost 0.01% (Naive Monotherapy)</title>
            <description>1 drop in the affected eye(s), administered in the evening in previously treatment naive subjects for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Bimatoprost 0.01% (Switched Monotherapy)</title>
            <description>1 drop in the affected eye(s), administered in the evening in subjects who were previously on another monotherapy treatment for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Bimatoprost 0.01% (With Adjunctive Therapy)</title>
            <description>1 drop in the affected eye(s), administered in the evening in subjects who are also receiving adjunctive therapy for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hyperemia Severity in the Study Eye</title>
          <description>Hyperemia is the engorgement of the blood vessels (redness) of the eye. Hyperemia was graded in the study eye on a 5 point scale where 0=None (Normal), 0.5=Trace (Trace reddish pink with no more than slight perilimbal injection), 1=Mild (Mild flush reddish color), 2=Moderate (Bright red color), and 3=Severe (Deep, bright, diffuse redness). 'Lower' categories refer to grades 0, 0.5 and 1, and 'higher' categories refer to grades 2 and 3. Change in hyperemia severity was classified as improved, no change or worsened based on the change in the hyperemia grading category from higher to lower, no change in category or lower to higher, respectively. The numbers of participants in each category are presented.</description>
          <population>Intent to Treat: all treated subjects with data at this time point</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191"/>
                    <measurement group_id="O2" value="149"/>
                    <measurement group_id="O3" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bimatoprost 0.01% (Naive Monotherapy)</title>
          <description>1 drop in the affected eye(s), administered in the evening in previously treatment naive subjects for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Bimatoprost 0.01% (Switched Monotherapy)</title>
          <description>1 drop in the affected eye(s), administered in the evening in subjects who were previously on another monotherapy treatment for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Bimatoprost 0.01% (With Adjunctive Therapy)</title>
          <description>1 drop in the affected eye(s), administered in the evening in subjects who are also receiving adjunctive therapy for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="248"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="248"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival Hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="248"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="257"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 30 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President Medical Affairs,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

